Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
90 hedge funds and large institutions have $95.2M invested in Chinook Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 28 increasing their positions, 20 reducing their positions, and 15 closing their positions.
5,427% more call options, than puts
Call options by funds: $608K | Put options by funds: $11K
53% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 15
40% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 20
10% more funds holding
Funds holding: 82 → 90 (+8)
13% less capital invested
Capital invested by funds: $110M → $95.2M (-$14.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$2.21M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.09M |
| 3 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$964K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$957K |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$711K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$4.63M |
| 2 |
JP Morgan Chase
New York
|
-$1.24M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$739K |
| 4 |
EAM
Erste Asset Management
Vienna,
Austria
|
-$483K |
| 5 |
Millennium Management
New York
|
-$436K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIM
101
Alambic Investment Management
Belvedere,
California
| – | -$29K | -2,140 | Closed |
|
|
MLICM
102
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$14.4K | -1,049 | Closed |
|
103
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$2K | -123 | Closed |
|
|
EI
104
Ellevest Inc
New York
| – | -$1K | -93 | Closed |
|
KDNY Hedge Fund Activity: Q2 2020 in Review
90 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q2 2020, worth a combined $95.2M — down 13% from $110M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new KDNY positions and 15 closed out — a net gain of 8 holders — while 28 added to existing stakes and 20 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $2.21M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $4.63M sold.
- 90 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q2 2020, up from 82 in Q1 2020.
- Funds reported $95.2M of Chinook Therapeutics, Inc. Common Stock stock for Q2 2020, down 13% quarter-over-quarter.
- 23 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q2 2020 and 15 closed out, a net change of +8 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q2 2020 was Suvretta Capital Management, an estimated $2.21M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q2 2020 was Lord, Abbett & Co, an estimated $4.63M sold.
Based on aggregated 13F filings for Q2 2020.